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a model in which both aystemic arterial and IC bFGF effectively promote
coronary collateral growth, 1PbFGF was not efficacious. A key difference
between parenterel and 1Padministration is directional (delivery via the vas-
cular lumen vs. abiuminal delivery). This factor may be responsible for the
lack of effect of 1PbFGF in this study.
-1 C-~pNatri.reti. PeptideMediatescGMP
Generation and Antimitogenic Actiona in Human
Coronary Vaacular Smooth Muscle Cells
J. Schirger, J.C. Burnett, Jr., C.-M. Wei. Mayo Clinic, Rochestec MN, USA
C-type natriuretic peptide (CNP) is an endothelial cell derived cardiovascular
peptide which mediates vasodilato!y and antimitogenic aclions. Previous
studies demonstrate that the biological actions of CNP are mediated through
the activation of a particulate guanylyl cyclase receptor and cGMP. To date,
it remains unclear as to the abilify of CNP to stimulate cGMP generation
and to inhibit proliferation in human coronay vaacular smooth muscle cells
(HCVSMCS). Therefore, the preaent studies were designed to determine
1) the effects of CNP upon cGMP generation in HCVSMCS and 2) the
antimitogenic actions of CNP upon endothelin-1 (ET-1)mediated proliferation
in HCVSMCS. We hypothesized that CNP increases cGMP generation in
HCVSMCS and inhibits the proliferative effect of ET-1 in HCVSMCS. To
test this hypothesis we determined cGMP by radioimmunoassay in cultured
HCVSMCSin the presence and absence of CNP.Additionally, cultured cells
were stimulated by ET-1 (1OL7M)in the presence and absence of CNP
(10-7M) and thymidine incorporation was determined.
cGMP (omol/ml) 2 hours 8 hours 24 hours
.. ,
Control 0.50l 0.10 0.45+ 0,05 0.65+ 0.15
CNP(10-7M) 0.95l 0.55 1.35i 0.45 2.80+ 1.00
ET-1 increased thymidine incorporation in HCVSMCS as compared to
.unstimulated cells (1362 & 288 vs 190 * 24 cptiwell, p < 0.05) and CNP
inhibited ET-1 mediate thymidine incorporation (298 l 51 vs 1362 + 288
cpm/well, p < 0.05). These studies supporl the concept that CNP is an im-
porlant activator of cGMP accumulation in human coronary vascular smooth
muscle cells and plays an important autocrine and paracrine role as an
inhibitor of mitogen-mediated proliferation of HCVSMCS.
1961-1181BaSiCFibrOb,aStG~O~~FaCtO~iSaCOrOnaW
Vasoconatrictor in Experimental
Hypercholeaterolemia
D. Hasdai, V. Mathew, R.S. Schwati, D.R. Holmes, Jr., A. Lerman. Mayo
Clinic, Rochestefi MN, USA
Beeic fibroblaat growth factor (bFGF) is a vasodilator which is dependent
on the endothelium-derived relaxing factor (EDRF) pathway. Hypercholes-
teroiemia (HC) is characterized by decreased corona~ EDRF activity. Thus,
we examined whether the reduced EDRF activity associated with HC results
in coronaty vasoconstriotion in response to bFGF. Intracoronary bFGF (0.02
@kg/rein) was infused at baseline and after 10 weeks of high-cholesterol
diet. In addition, L-NG-momo-methyl-arginine (L-NMMA), a nitric oxide syn-
theee inhibitor, was infused intracoronary at baseline 5 (r@kg/min) with and
without bFGF. Percent change in coronaw artew diameter (%ACAD) and
coronary blood flow (%ACBF) were calculated based on coronaty quantita-
tive angiography and Doppler: *P <0.05 vs. baseline, ‘p -=0.05 vs LNMMA
and baseline bFGF.
bFGF(n= 5) bFGF(n= 5) LNMMA LNMMA+ bFGF
Saseline 10 wks, HC (n= 4) (n= 7)
%ACAD 12&5 -14 +6* –21 * 4 –75 i lzt
%ACBF 33*33 –45 *6* 45* 5 –89+9t
Conclusions: BFGF is a mild coronay vasodilator in the steady-state.
However,endogenous (HC) and exogenous (by L-NMMA) inhibition of EDRF
activity resulted in coronaty vasoeonstrietion in response to bFGF. These
studies auggeat that the coronary vasomotor effects of bFGF are regulated
by the status of the EDRF pathway.
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Secretion of Brain Natriuretic Peptide in Cultured
. .Human Coronary Vascular Smooth Muscle Cells:
A New Autocrine and Paracrine Role for the
Natriuretic Peptide System
C.-M. Wei, D.M, Heublein, J.C. Burnett, Jr,, Cardiorerra/Research
Laboratory Mayo Clinic, Rocheste< MN, USA
Brain natriuretic peptide (BNP) is a peptide of cardiac origin which regulates
plasma volume and also vascular tone and growth. Recently, we have re-
ported that BNP is a potent inhibitor of endothelin-1 mediated proliferation
in human coronary vascular smooth muscle cells (HCOVSMC).While BNP
has been reported to be produced and released from atrial and ventricular
myocardium, we investigated the hypothesis that BNP may be present and
secreted from human coronary vascular smooth muscle cells. Therefore, the
present study was designed to investigate the secretion of BNP in cultured
human coronary vascular smooth muscle cells (HCOVSMC:Clonetics, San
Diego, CA). BNP and its second messenger cGMP in culture media were
determined by radioimmunoassay.The presence of BNP was determined by
immunohistochemical staining using ahuman BNP polyclonal antibody. BNP
immunoreacfivity was significantly increased in culture media after 46 hours
incubation compared with baseline (323 + 85 vs 11 + 4 pg/ml, p < 0.05).
Cyclic GMP immunoreactivity also increased in coronary vascular smooth
muscle cells after culture (0.4 * 0.03 vs 0.05 + 0.01 pmol/min, p < 0.05), To
confirm the presence of BNP and cGMP in HCOVSMC,two stage immuno-
histochemieel staining was petformed, In these studies, BNP and c’GMP
stained positively in cytoplasm of HCOVSMCwhile non-immune staining was
negative, The current study demonstrates that BNP is secreted by cultured
HCOVSMC in association with an increase in cGMP accumulation. These
date suggest a probable autocrine and paracrine role for BNP as a peptide
of coronary vascular smooth muscle origin which may participate in corona~
vascular smooth muscle regulation.
m961 120 Effect of 17&Estradiol Treatment on Intimal
Apoptoais and Cell Proliferation in an
Experimental Atheroscleroaia Model
J, Kamenz,H.Hanke,S. Hanke,C. Lenz, H. Kahn, V. Hombach. University
of U/m Medical Centec Div. of Cardio/ogN U/m, Germany
It has been shown that administration of 17& Estradiol does reduce intimal
thickening in experimental atherosclerosis. So far the mechanism of the
atheroprotective effect of estrogen is not well understood. Aim of the present
study was to determine the effect of estrogen on intimal apoptosis in compar-
ison to cellular proliferation during plaque development in an experimental
atherosclerosis model, Thirty female New-Zealand rabbits’were included in
this study. Six rabbits served as a control group without cholesterol feeding
(CHOL) or hormone treatment, Twenty-four rabbits received a 0,5% CHOL
diet for 12 weeks and were separated in 3 different groups:
Group A only CHOL, Group B CHOL + ovareetomy, Group C CHOL +
ovarectomy + 17fJ-Estradiol1 mg/kg BW/week for 12 weeks, The aortic arch
was then histologically and morphometrically analyzed. For in-situ detection
of apoptosis the TUNEL-technique (TdT-mediatad dUTP nick end labeling)
was used. Bromodeoxyuridine-labeling allowed the determination of cells
undergoing DNA-synthesis. Resu/ts:
Studygroup Intimalarea(mm2) Apoptoiiccetls/mm2 Proliferatingcella/mm2
Controln = 6 <0.1 0 0
GroupA n= 6 4.5+ 2.8 4,4i 1.7 46.7 + 16.3
GrOUD B n = 8 4,s + 1,7 3.7 * 1.5 45,6 + 11,9
GroupC n = 6 1.4 * 0.9(p< 0,05) 6.1 + 4,3 21.6 + 22.6 (p < 0,05)
In summary,continuous estrogen treatment during atherosclerotic plaque
development seems to reduce intimal cell proliferation and to have no influ-
ence on the apoptosis rate in the intima, resulting in a significantly smaller
intimal area.
1961-121 I AssociatiOnofTransformingGrowthFector-bet8
Isoforms with Coronary Plaque in Patienta with
Coronary Ischemia
H. Ueda, M. Imazur K. Sumii, H. Yamamoto, K. One, F.Tadehara,
Y. Hayashi, W, Yaeui, M. Yamakido. Hiroshima Univeraify Schoo/ of
Medicine, Hiroshima, Japan
Transforming growth factor (TGF) $sare important cyfokines in the vascular
system. But an association between their expression in coronary Ieaionsand
clinical pathophysiology has not been fully elucidated. We studied speei-
mens of coronary lesions obtained at directional coronary atherectomy in 59
patients with the following diagnoses: stable angina (SA, n = 8), acute coro-
nary syndromes (ACS, n = 21), or restenosis (RS, n = 30). The specimens
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SA (n= 8) ACS (n = 21) RS (n = 30)
TGF-B1 0.75 i 0.16 1.81 + 0.25” 1.60 + 0.18”
TGF-)2 1.13 * 0,30 2,24 + 0.17*t 1,40 i 0.15
TGF+3 1.63 + 0.26 2.36 + 0.16” 2,27 + 0.13$
TBR-I 2.38 + 0,18 2.36 i 0.16 2.63 * 0.10
T@R-11 2.13 + 0.23 2.05 i 0.19 2.32 + 0.13
Intimalhyperplaaia 36% 71% 90%”
Neovascularization 13”A 57%* 40”/0
“ P <0.05 vs. SA, t P -=0.05 vs. RS
were immunohistochemically analyzed for the expression and localization of
TGF+J (TGF+?l, -fJ2, and +3) and its receptor (TglR-1and -Ii) isoforms ‘in
corona~ plaques (graded from Oto 3).
Immunoreactivity for TGF-A’sand TPRS was observed in the cytoplasm
of smooth muscle cells (a-actin positive), nonfoamy macrophages (CD68
positive) and endothelial cells (CCf31positive). High numbers of TGF-A9and
TBR-positivecells were seen in intimal hyperplasia (IH) and naovascularized
lesions with hemorrhage or inflammation. Moreover, in IH, the expression
level of each TGP-p isoform varied. In conclusion, our results suggeat that
TGF-p isoforms are involved in thepathogenesis of coronaty lesions in acute
coronary syndromes and restenosis, and that they have apacific functions in
the coronary plaque formation.
El962 Microvascular, Thrombotic, snd Spastic
Angina
Monday,March 17, 1997, 3:00 p.m.-5:OOp.m.
AnaheimConventionCenter,HallE
PresentationHour:3:00p.m.-4:OOp.m.
D96290 ExerciseInducedChengee of Fibrinolytic endThrombotic Potentiel in Runners Following the
IOOth Boeton Marsthon
J.J. Stec, G.H. T~fler, 1.Lipinska, P.M. Ridker, A.J. Siegel. FfarvardMedica/
School, Boston, MA, USA
Although moderate physical activity ia cardioprotecfive, strenuous exertion
has bean occasionally associated with the triggering of acute myocardial
infarction (AMI). Since thrombosis plays an important pathogenetic role in the
onset of AMI, we examined the effect of marathon running on the fibrinolytic
and thrombotic potential in 24 healthy male participants, mean age 50 + 10
years. The subjects had blood drawn the morning before and within 5 hours
following the IOOthBoston Marathon. Values are mean + standard error of
mean. Paired t-teats were performed.
Befora ‘Aftar o-value
Fibrfnolyticactivity(mmz) 72& 11 173+ 14 0.001
D-Dimer (rig/ml) 180+26 405 &42 0.001
von Willebrsndfsctor (“A) 69 k 9 21O* t4 0.001
C-resctlveprotein (nglml) t47 k35 650+ 110 0.001
Fibrinogen(mg/dl) 2ti* 10 234 * 9 0.03
Marathon running resulted in a significant increase in fibrinolytic activity
and D-Dimer, von Willebrsnd factor and C-reactive protein. Fibrinogen levels
were alightly reduced.
In these healthy participants activation occurred of both fibrinolysis and
prothromhtic factors suggesting a hemostatic balance. Further studies are
needad todetermine theeffecfof prolonged strenuous exerciseonthrombotic
potential, particularly in subjects at increaeed cardiovascular risk.
D96291 Attenuated Success Rate of Thrombolysis forAcute Myocardjal Infarction by Reduced
Endogenous Fibrinolysis
T.K. Nordf, M. Moaer, B. Kohler, K. Peter, C. Bode. Med. Universit#ts/dini/r
Heidelberg, Germany
Resistance to thrombolysis in acute myocardial infarction (AMI) constitutes
a major limitation of this form of therapy. To delineate the contribution of the
various components of the blood coagulation system (i.e. platelet function,
thrombin activity, and endoganous fibrinolytic activity), platelet aggregation
(induced by 2 WMADP), thrombin antithrombin complexes (TAT,measured
by ELlSA), and plasminogen activator inhibitor type-1 (PAI-1,measured both
by ELISA and by using chromogenic substrate S-2251) were determined in
31 patients with AMI at O, 1, and 2 h after initiation of thrombolytic therapy.
Patienta were treatad with fibrin-specific piasminogen activators (t-PA, r-
PA), patency was assessed by coronary angiography at 1.5 h and gradad
according to the TIMI criteria. With respect to platelet aggregation (both slope
and maximum) and TAT levels there was no significant association with the
TIMI grade. TATlevels at Oh even tended to be higher in successfully treated
patients: 2.1 + 0.0 rig/ml with TIMI grade O, 1.6 + 0.2 with [, 5,2 + 2.1
with 11,and 5.0 + 1.3 with Ill (+ SEM). However, plasma concentrations of
PAI-1 were significantly increased in patients with unsuccessful outcome in
comparison to those with successful treatment: 39 * 1 nglml with TIMI grade
0, 31 + 7 with 1,30 + 7 with 11,and 24 + 3 with Ill (+ SEM, p < 0.05). Plasma
activity of PAI-I measured before thrombolysis showed parallel reeults. No
difference could be found for the thrombolytic agent used. Thus, resiatanca
tothrombolyfic therapy in AMI appears to be caused by reduced endogenous
fibrinolysis secondaty to increased PAI-1 in plaama rather than by increaead
platelet orthrombin activity. Patients with elevated baseline PAI-I may profit
more consistently from alternative reperfusion strategies.
962-92 Abnormal Microvascular Responses In Cardiac
Syndrome X Csnnot Be Explained Solely By The
Praeance of Epicardial Subangiographic Atharoma
I.D. Cox, J.R. Clague, J.P. Bagger, D.E. Ward, J.C, Kaski. St. George’s
Hospital, London, UK
Aim.’ To study tha relationship between coronay microvascular rasponses
and epicardial sub-angiographic atheroma (SAA) in syndrome X.
Patients: We studied 9 patients (8 women; median age 55, range 43-72)
with syndrome X (anginal pain, positive exercise ECG and normal coronary
angiogrsphy) who were undergoing repeat corona~ angiography due to
persistent disabling anginai pain despite anti-anginal therapy. None had doc-
umented coronary spasm, blood pressure > 150/95 mmHg, left ventricular
hypertrophy or cholesterol >8.5 mmol/1,and all were non-smokers.
Methods: Vasoactive drugs were stopped ?5 half-lives prior to catheter-
isation, Repeat angiography was completely normal in all caaes. Coronary
flow velocity responses during intracoronary infusion of acefylcholine (ACh
– O, 10-7 and 10-6M) and following an intracoronary bolus of 300 Kg glyc-
eryl trinitrate (GTN) ware assessad uaing a Doppler ultrasound guide-wire
deployad in tha proximal LAD artery. Simultaneous quantitative angiography
was performed to enable calculation of coronary flow volume resewa i.e.
the ratio of baseline to peak flow volume for each dilator (CFR-ACWGTN).
Intimal thickening due to SAA was measured by intravascular ultrasound at
1 mm intervals through tha IAD.
Resu/ts: The median CFR-ACh was 1.78 (range 1.3-4.5) and was clas-
sified as abnormal (< 2) in 5 patients; CFR-GTN was =- 2 in all oaees. Six
patients had significant intimal thickening (> 0.3 mm) and the median mexi-
mal intimal thickness was 1.0 mm (range O-1.2 mm) Two of the five patients
with CFR-ACh <2 had no significant SAA and there was no significant cor-
relation betwaen the saverity of SAA and CFR-ACh (rho = 0.054, p = NS;
Spearman’s Rank Correlation Coefficient).
Cone/usions:Abnormal endothalium-dependent microvascular responses
in syndrome X patients cannot be explained simply by the presence of SAA.
1962-931ThelmpactOfCoronary Flow ReSef’veand,n@in
Resistance on Myocardial Energy Metabolism in
Syndrome X
HE. Batker, H.S. Sonne, J.P. Bagger, T.T.Nielsen. Department nf
Cardiology Skejby University Hospital, Aarhus, Denmark
Itremains controversial whether myocardial ischemia ia preaent in patients
with syndrome X. Myocardial energy efficiency may be compromised due to
an attenuated increment of carbohydrate oxidation during pace strass. To
evaluate the influence of coronary flow reserve and myocardial subatrata up-
taka oncerdiacenergy efficiency,weusadcoronary sinuacatheterization and
studied myocardial metabolism at rest and during pa(e streas in 18 corrsac-
utive patients with syndrome X and in 10 mntrol subject (C). The patiants
were subclassified as microvascular angina (MA, n =8) in the prasence of a
reduced coronary flow reserve (< 2.5) or no microvascular angina (non-MA,
n = 1“0)if coronary flow reserve was presetved (?2.5). Rasu/ts: Patients with
non-MA revealedfasting hyparinsulinemia (55* 5VS.MA: 28*5 and C: 29 +
2pmol x 1-1, p < 0.05) and increased arterial concentration of fraefatlyacids
(FFA) (1,41 + 0,19 vs. MA: 1.22+ 0.15 and C: 1.01 + 0.12 mmol x 1-1, p <
0.05). During pacing, myocerdial uptake of FFAwas increased in the non-MA
patients. Net myocardial lactate release was not observed in any patiants.
In all subjects, myocardial FFA uptake correlated positively while glucose
upfake correlated invarsely with arterial concentrations of FFA. Myocardial
energy expenditure, and net carbohydrate- and lipid oxidation were similar in
the three groups. Conclusion: Not only angina pectoris and ST-segment de-
pression but also a decreased corona~ flow reaerve and insulin resistance,
associated with a relatively increased myocardial FFA uptake, coexist with
presarved myocardial energy efficiency in patients with syndrome X.
